Skip to Main Content

Hey, happy Wednesday from your trusty Ed Silverman proxy: This edition of Pharmalot is penned by Meghana of Team Readout. Take a healthy break (as I am) from your family’s holiday crazy with some biopharma news:

The clinical trial process of India’s generic drug business is deeply flawed, as a new Reuters report points out. The testing done at Indian clinical research organizations is critical in the approval process of hundreds of medications around the world — but many don’t follow international clinical trial guidelines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED